HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $30 to $35.
HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $30 to $35.